HomeAI · summaries
Storia in 5 fonti
Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis
Zasocitinib outperformed deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis, according to topline data. As Healio previously reported, zasocitinib (Takeda) is an investigational, highly selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis. In the phase 3, head-to-head trial, researchers found that
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
- ·
morningstar.com
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral…
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
